Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Invested Capital (2016 - 2025)

Voyager Therapeutics' Invested Capital history spans 11 years, with the latest figure at $196.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 34.59% year-over-year to $196.1 million; the TTM value through Dec 2025 reached $196.1 million, down 34.59%, while the annual FY2025 figure was $196.1 million, 34.59% down from the prior year.
  • Invested Capital for Q4 2025 was $196.1 million at Voyager Therapeutics, down from $219.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $340.9 million in Q1 2024 and bottomed at $59.0 million in Q4 2022.
  • The 5-year median for Invested Capital is $197.6 million (2023), against an average of $188.6 million.
  • The largest annual shift saw Invested Capital crashed 47.41% in 2021 before it soared 300.41% in 2023.
  • A 5-year view of Invested Capital shows it stood at $95.1 million in 2021, then tumbled by 37.91% to $59.0 million in 2022, then skyrocketed by 300.41% to $236.3 million in 2023, then rose by 26.84% to $299.8 million in 2024, then plummeted by 34.59% to $196.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Invested Capital are $196.1 million (Q4 2025), $219.8 million (Q3 2025), and $243.9 million (Q2 2025).